Related Experiment Video
Updated: Jun 9, 2025
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Pentoxifylline in COVID-19 and considerations for its research in long COVID
Ahmed Ramzi1, Subhia Maya2, Nadeen Balousha3
1Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Insights
Pentoxifylline (PTX) as an add-on to standard COVID-19 treatment may shorten hospital stays and improve inflammatory markers. While its effect on mortality is unclear, PTX shows promise for managing acute COVID-19 and potentially preventing or treating long COVID.
Area of Science:
- Pharmacology
- Infectious Diseases
- Critical Care Medicine
Background:
- Pentoxifylline (PTX) influences blood components and vessels, impacting conditions like COVID-19.
- Research is exploring PTX for acute COVID-19 due to its effects on severity markers.
- Increased focus on long COVID post-vaccination necessitates contextualizing acute COVID-19 data.
Purpose of the Study:
- To systematically review and meta-analyze clinical studies on Pentoxifylline (PTX) in COVID-19 patients.
- To evaluate PTX's efficacy as an adjuvant therapy for acute COVID-19.
- To assess PTX's potential role in managing long COVID.
Main Methods:
- Comprehensive search of various databases until July 2024.
- Inclusion of all primary clinical studies investigating Pentoxifylline (PTX) in COVID-19.
- Systematic review and meta-analysis of collected data.
Main Results:
- PTX as adjuvant therapy generally reduced hospitalization duration and improved inflammatory markers.
- Impact of PTX on mortality rates in acute COVID-19 was inconsistent across studies.
- Meta-analysis confirmed a significant reduction in hospitalization duration with PTX use.
- Adverse events associated with PTX were minimal.
Conclusions:
- Adding Pentoxifylline (PTX) to standard COVID-19 therapy may significantly shorten hospital stays and improve inflammatory markers.
- The effect of PTX on mortality in acute COVID-19 remains inconclusive.
- PTX appears to be a safe add-on treatment for acute COVID-19 and may help mitigate long COVID risks and symptoms.
Introduction:
Pentoxifylline (PTX) affects most blood components and the blood vessels, potentially modulating various conditions. Due to its impact on markers linked to COVID-19 severity, research has explored PTX for acute COVID-19. Following the widespread administration of COVID-19 vaccinations, there has been a notable and consistently growing increase in research focusing on long COVID. Consequently, our examination of relevant acute COVID-19 data shall additionally be contextualized into long COVID research.
Methods:
Various Databases were searched until July 2024 for all primary clinical studies on Pentoxifylline (PTX) in COVID-19.
Results:
Studies were on acute infection with SARS-CoV-2 where PTX was an adjuvant to standard therapy for ethical and practical reasons under the circumstance. PTX generally reduced hospitalization duration and improved some inflammatory markers, but its impact on mortality was inconsistent. Adverse events were minimal. Meta-analysis revealed a significant reduction in hospitalization duration.
Conclusion:
This systematic review and meta-analysis suggest that adding pentoxifylline (PTX) to standard COVID-19 therapy may significantly reduce hospitalization duration and improve some inflammatory markers. However, its impact on mortality rates is inconclusive. Adverse events are minimal. PTX can be favorable as an add-on in managing acute COVID-19 and could reduce the risk of long COVID, as well as assist in managing many of its most common symptoms.
More Related Videos
05:19Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation